2021 Updates in Treatment Strategies for Management of Triple Negative Breast Cancer
2021 Updates in Treatment Strategies for Management of Triple Negative Breast Cancer is a CME-accredited activity that features leading experts in breast cancer who will provide a comprehensive overview of current and emerging strategies for management of triple-negative breast cancer. The goal of this activity is to improve the knowledge, competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with triple negative breast cancer. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in molecular testing and targeted-therapies for triple-negative breast cancer. Expert faculty will aim to place the role of different therapeutic agents in clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.
Cancer care professionals including:
- Practicing oncologists
- Oncology fellows
- Oncology nurses
- Nurse practitioners
- Physician assistants
Upon successful completion of this educational activity, participants will be able to:
- Review frequent molecular abnormalities in triple-negative breast cancer, and appropriate timing of testing to detect these abnormalities.
- Outline efficacy and toxicities of immune checkpoint inhibitors, PARP inhibitors, Trop-2inhibitors, and other chemotherapy agents in management of triple-negative breast cancer.
- Identify the role of neoadjuvant and adjuvant systemic therapy options in curative-intent treatment of triple-negative breast cancer, including the role of chemotherapy, immune checkpoint inhibitors and PARP inhibitors.
- Incorporate appropriate sequencing of treatment options in patients with metastatic triple-negative breast cancer.
- Integrate emerging evidence in precision oncology into treatment paradigms for treatment of triple-negative breast cancer.
Conference Chair: To be announced
All times below are listed in Pacific Standard Time
|7:15AM - 7:45AM|
7:45AM - 8:00AM
|Welcome and Faculty Introduction|
|8:00AM - 8:25AM|
Immune-Checkpoint Inhibitors in Management of Triple-Negative Breast Cancer
|8:25AM - 8:50AM|
Germline Genetic Testing and PARP Inhibitors in Management of Triple-Negative Breast Cancer
|8:50AM - 9:00AM|
|9:00AM - 9:30AM|
|9:30AM - 9:55AM|
Efficacy and Toxicities of Sacituzumab Govitecan in Management of Metastatic Triple-Negative Breast Cancer
|9:55AM - 10:20AM|
NGS, ctDNA and Other Precision Approaches for Identification of Novel Therapies in Management of Triple-Negative Breast Cancer
|10:20AM - 10:30AM|
|10:30AM - 11:00AM|
- 2.50 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 0.00 Attendance
- 2.50 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.50 Contact Hours.
- 0.00 Participation